Company profile
Drugs Made In America Acquisition II Corp.
NASDAQ: DMIIR · Financial Services · Financial - Conglomerates
#876 of 1,011 Financial Services companies by revenue
EA Score
——FH 56DQ —GM —SS 12
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$4.2M
Employees
2
as of 2026-09-02
Market cap
$5.5M
as of 2026-09-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income$4.2M$4.2M2025
Operating income-$1.3M-$1.3M2025
Total assets$505.0M$505.0M2025
Liabilities$17.8M$17.8M2025
Equity$487.2M$487.2M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Drugs Made In America Acquisition II Corp.’s revenue?
Drugs Made In America Acquisition II Corp. booked $0 in FY2025 revenue — among the slowest-growing Financial Services companies we track, at a Infinity% net margin.
Peers · Financial Services
BTC Development Corp.——Art Technology Acquisition Corp.——Patriot Resources Corp.25DHighview Merger Corp.——Q Precious & Battery Metals Corp.——Bravern Ventures Ltd.——Neighbors
Broward →Key facts
CEORoger Bendelac
SectorFinancial Services
IndustryFinancial - Conglomerates
HeadquartersFort Lauderdale, FL
ExchangeNASDAQ: DMIIR
Employees2
IPO date2025-12-04
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.